SEATTLE, Jan. 8 /PRNewswire-FirstCall/ -- Dendreon Corporation (NASDAQ: DNDN) today announced that management will present at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 15, 2009 at 11:00 a.m. PT. A live audio webcast of the presentation will be accessible through the Investor Relations section of the Dendreon website, http://www.dendreon.com/. If you are unable to listen to the live webcast, it will be archived on the site following the presentation. To access the replay, go to the Investor Relations section of the website. Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets Trp-p8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/. DATASOURCE: Dendreon Corporation CONTACT: Jennifer Williams, Investor Relations, Dendreon Corporation, +1-206-829-1500 Web Site: http://www.dendreon.com/

Copyright